India’s engagement with stem cell science has traversed a remarkable arc—from early exploratory research to the threshold of clinically meaningful, technology-driven regenerative medicine. Yet, the next phase of evolution will not be defined merely by incremental scientific advances, but by the country’s ability to translate biological promise into scalable, evidence-based, and equitable healthcare solutions. This transition is being shaped by converging technological trajectories—gene editing, tissue engineering, artificial intelligence, and advanced manufacturing—while simultaneously demanding the creation of robust foundational infrastructure. Among these, national biobank repositories stand out as a strategic cornerstone, enabling precision, reproducibility, and acceleration of translational pipelines.
Bajpai et al. (Wed,) studied this question.